Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

BACKGROUND The importance of plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA in pregnant women in relation to the other factors known to influence the risk of transmission of infection to their infants is incompletely defined. We studied the relation of maternal plasma HIV-1 RNA levels to the risk of perinatal transmission and the timing of transmission. METHODS We measured plasma HIV-1 RNA serially in 552 women with HIV-1 infection who had singleton pregnancies. The status of infection in their infants was assessed by culture of blood and further classified as early (if a culture of blood obtained within the first two days of life was positive) or late (if a culture of blood obtained in the first seven days of life was negative but subsequent cultures were positive). The rates of transmission at various levels of maternal plasma HIV-1 RNA were analyzed by tests for trend, with adjustment for covariates by stratification and logistic regression. RESULTS Increasing geometric mean levels of plasma HIV-1 RNA were associated with increasing rates of transmission: the rate was 0 percent among women with less than 1000 copies per milliliter (0 of 57), 16.6 percent among women with 1000 to 10,000 copies per milliliter (32 of 193), 21.3 percent among women with 10,001 to 50,000 copies per milliliter (39 of 183), 30.9 percent among women with 50,001 to 100,000 copies per milliliter (17 of 55), and 40.6 percent among women with more than 100,000 copies per milliliter (26 of 64) (P<0.001). The treatment status of one woman was unknown. The highest rate of transmission was among women whose plasma HIV-1 RNA levels exceeded 100,000 copies per milliliter and who had not received zidovudine (19 of 30 women, 63.3 percent). Neither higher HIV-1 RNA levels early in pregnancy nor higher levels late in pregnancy were associated with the timing of infection in the infants. CONCLUSIONS In pregnant women with HIV-1 infection the level of plasma HIV-1 RNA predicts the risk but not the timing of transmission of HIV-1 to their infants.

[1]  J. Read,et al.  The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies: the International Perinatal HIV Group , 1999 .

[2]  F. Parazzini Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial , 1999, The Lancet.

[3]  D. Levy,et al.  Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[4]  A. Berrebi,et al.  Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. , 1998, JAMA.

[5]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[6]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[7]  C. Macken,et al.  Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant , 1997, Nature Medicine.

[8]  C. Rouzioux,et al.  Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant , 1997 .

[9]  L. Kalish,et al.  After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. , 1996, The Journal of infectious diseases.

[10]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[11]  A. Adimora,et al.  Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. , 1996, JAMA.

[12]  L. Mofenson,et al.  Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission , 1996, AIDS.

[13]  M. Sim,et al.  Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. , 1996, JAMA.

[14]  D. Hom,et al.  Maternal HIV-1 RNA serum levels at delivery and vertical transmission in Uganda. , 1996, Pediatric AIDS and HIV infection.

[15]  P. Stratton,et al.  The Women and Infants Transmission Study (WITS) of Maternal-Infant HIV Transmission: Study Design, Methods, and Baseline Data , 1996 .

[16]  O. Weislow,et al.  Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Martha Barry,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Connor E, Sperling R, Gelber R, et al. N Engl J Med 1994; 331: 1173-9 , 1995 .

[18]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[19]  S. Nachman,et al.  Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Gelman,et al.  Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.

[21]  D. Wara,et al.  Proposed definitions for in utero versus intrapartum transmission of HIV-1. , 1992, The New England journal of medicine.

[22]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .

[23]  J. Bremer,et al.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories , 1992, Journal of clinical microbiology.

[24]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[25]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[26]  Nathan Mantel,et al.  Chi-square tests with one degree of freedom , 1963 .

[27]  C. Katlama,et al.  Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. , 1997, The Journal of infectious diseases.